IN LANDMARK MOVE, FDA APPROVES CANCER DRUG FOR A BIOMARKER NOT A TISSUE

MedCity News  May 24, 2017

Dr. Scott Tomlins, Strata's co-founder and Laboratory Director, comments on the accelerated approval of Keytruda for MSI-H and dMMR cancers and the opportunity to accelerate the approval of additional precision therapies in biomarker-defined patient populations. At Strata Oncology, we believe that by institutionalizing tumor sequencing and clinical trial participation across a large network of hospitals, we can help usher in the next wave of biomarker-guided precision medicine approvals. Read the article here.



UAB - CLINICAL SITE PARTNER IN THE NEWS

Dr. Eddy Yang of UAB and Strata Oncology were highlighted in a video about the progressive work the hospital is doing to impact cancer patient care. Click here to see the video.

Birmingham, AL, May 19, 2017







 

Contact:

media@strataoncology.com

734-527-1000

.